Infant Formula HMO Composition for Reduced Allergic Sensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for nutritional compositions, such as infant formulas, that can prevent or reduce the development of allergic sensitization in infants, as existing formulas lack the specific human milk oligosaccharides (HMOs) that effectively modulate the immune system and there is uncertainty over the optimal levels of these HMOs for preventing allergies.
Innovation Solution
Infant formulas containing intermediate levels of 2′-fucosyllactose (2′FL) and lacto-N-neotetraose (LNnT), specifically 0.8-2.5 g/L and 0.05-0.2 g/L, respectively, are formulated to prevent or reduce allergic sensitization in infants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If infant formulas contain high levels of HMOs (2′FL and LNnT), then the immune modulation effect is enhanced, but the risk of adverse effects increases and manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by establishing specific concentration ranges for HMOs (2′FL: 0.8-2.5 g/L, LNnT: 0.05-0.2 g/L) to optimize immune modulation effectiveness while avoiding adverse effects. This quantitative parameter optimization resolves the contradiction between enhancing therapeutic effect and preventing harmful overexposure.
2Reliability
If infant formulas contain high levels of HMOs (2′FL and LNnT), then the immune modulation effect is enhanced, but the manufacturing complexity and cost increase
Solution Approach 1:
The patent defines precise HMO concentration parameters (2′FL: 0.8-2.5 g/L, LNnT: 0.05-0.2 g/L) that optimize immune modulation while simplifying manufacturing by establishing clear formulation targets. This parameter standardization resolves the contradiction between achieving therapeutic effectiveness and maintaining manufacturing simplicity.
3Ease of manufacture
If infant formulas contain low levels of HMOs (2′FL and LNnT), then the manufacturing is simpler and safer, but the immune modulation effectiveness is reduced
Solution Approach 1:
The patent establishes minimum effective concentration thresholds (2′FL: 0.8 g/L, LNnT: 0.05 g/L) that ensure immune modulation effectiveness while maintaining formulation simplicity. This parameter optimization resolves the contradiction between ease of manufacture and therapeutic effectiveness by defining the lowest effective doses.
4Ease of manufacture
If infant formulas contain low levels of HMOs (2′FL and LNnT), then the manufacturing is simpler and safer, but the allergic sensitization prevention effect is reduced
Solution Approach 1:
The patent defines minimum protective concentration levels (2′FL: 0.8 g/L, LNnT: 0.05 g/L) that effectively prevent allergic sensitization while keeping formulations simple and safe to manufacture. This parameter optimization resolves the contradiction between manufacturing ease and allergy prevention effectiveness.
Data Source
AI summary
An infant formula for use in preventing or reducing the occurrence of allergic sensitisation in an infant, wherein the infant formula comprises 0.8-2.5 g/L 2′-fucosyllactose (2′FL) and/or 0.05-0.2 g/L lacto-N-neotetraose (LNnT).